Volume de-escalation in radiation therapy: state of the art and new perspectives

ConclusionFurther clinical trials are necessary to improve the identification of suitable patient cohorts and the extent of possible volume de-escalation that does not compromise tumor control.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

CONCLUSIONS: Simultaneous CRC and CRLM resections seem to be safe when patients are carefully selected, also considering the risk of recurrence concerning oncologic outcomes. The pre-planning of simultaneous resection is mandatory to plan trocar positioning, procedure sequencing, and patient position. PMID: 32490901 [PubMed - in process]
Source: Acta Cirurgica Brasileira - Category: Surgery Authors: Tags: Acta Cir Bras Source Type: research
Publication date: Available online 3 June 2020Source: Carbohydrate PolymersAuthor(s): Ben Newland, Carmine Varricchio, Yvonne Körner, Franziska Hoppe, Christian Taplan, Heike Newland, Dimitri Eigel, Giusy Tornillo, Dagmar Pette, Andrea Brancale, Petra B. Welzel, F. Philipp Seib, Carsten Werner
Source: Carbohydrate Polymers - Category: Biomedical Science Source Type: research
Publication date: Available online 3 June 2020Source: Carbohydrate PolymersAuthor(s): Zhuodong Chai, Chao Teng, Lei Yang, Lianjie Ren, Zhongyue Yuan, Siyuan Xu, Manman Cheng, Yanmei Wang, Zhen Yan, Chao Qin, Xiaopeng Han, Lifang Yin
Source: Carbohydrate Polymers - Category: Biomedical Science Source Type: research
CONCLUSION: a Navigation Program was developed adapted to the Brazilian reality, and attributions of the navigators were created. PMID: 32491120 [PubMed - in process]
Source: Revista Latino-Americana de Enfermagem - Category: Nursing Authors: Tags: Rev Lat Am Enfermagem Source Type: research
Publication date: Available online 3 June 2020Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Houhe Liu, Yusi Quan, Xinlin Jiang, Xiaotian Zhao, Yi Zhou, Jijun Fu, Lingran Du, Xiaoya Zhao, Jing Zhao, Lu Liang, Di Yi, Yugang Huang, Guodong Ye
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
Publication date: Available online 3 June 2020Source: Sensors and Actuators B: ChemicalAuthor(s): Hui-Min Wang, Ai-Jun Wang, Pei-Xin Yuan, Jiu-Ju Feng
Source: Sensors and Actuators B: Chemical - Category: Chemistry Source Type: research
Chem. Commun., 2020, Accepted Manuscript DOI: 10.1039/D0CC03589K, CommunicationLongbing Ling, Haizhou Yu, Muhammad Ismail, Yan-Ping Zhu, Yuan Du, Junhui Qi An amphiphilic dimeric-podophyllotoxin (PODO) phospholipid was synthesized to assemble into liposomes as a combination of prodrug and nanocarriers. Results have demonstrated cell membrane-like delivery system possessed an improved cellular uptake... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - Category: Chemistry Authors: Source Type: research
Authors: Cheng J, Yang A, Cheng S, Feng L, Wu X, Lu X, Zu M, Cui J, Yu H, Zou L Abstract BACKGROUND MicroRNAs (miRNAs) are attracting substantial interest as promising noninvasive biomarkers for gastric cancer (GC). Our study aimed to identify circulating miRNAs that are potential noninvasive markers for precancerous lesions and early gastric cancers (EGCs). MATERIAL AND METHODS Plasma specimens were obtained from 58 gastritis subjects, 54 patients with precancerous lesions, and 38 EGC patients for study. RESULTS Significant differences in the plasma expression levels of miR-19a-3p, miR-22-3p, miR-146a-5p, and miR-483-5p (all P
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
CONCLUSION: Further clinical trials are necessary to improve the identification of suitable patient cohorts and the extent of possible volume de-escalation that does not compromise tumor control. PMID: 32072318 [PubMed - indexed for MEDLINE]
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Tags: J Cancer Res Clin Oncol Source Type: research
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Brain Cancers | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Databases & Libraries | Head and Neck Cancer | Lymphoma | Neurology | Pancreas | Pancreatic Cancer | Radiation Therapy